OakChart

EDAP TMS SA ADR

FOCLHealthcare·Medical Distribution·France·Micro·NASD·Nov 10 • 3:59 PM ET

3.500.00 (0.00%)
2026-11-11 14:56 CET
Market cap
165.27 USD m
Revenue, TTM
62.74 USD m
Net income, TTM
-37.49 USD m
Free cash flow, TTM
-18.30 USD m
EPS diluted, TTM
-0.99
P/E
-
Compare

Price

FOCL against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.006.00643K1.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FOCLclose 3.5020-day 4.0850-day 4.20200-day 4.413.50

45.3% under 6.40 on 4 Aug 2026. Last 15 sessions, 36.9% high to low

Profile

FOCL
52-week range, 35% of the way up
1.926.40

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Employees289
IPOAug 01, 1997
Beta0.00
ATR, 14d0.33
Rel volume0.00
Short float0.78%
Insider own0.53%
Inst own40.16%

Snapshot

6 groups

Valuation

Index-
Market Cap165.27M
Enterprise Value146.59M
Income-37.49M
Sales62.74M
Book/sh0.76
Cash/sh1.19
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees289
IPOAug 01, 1997

Ratios

P/E-
Forward P/E-
PEG-
P/S2.63
P/B4.60
P/C2.94
P/FCF-
EV/EBITDA-
EV/Sales2.34
Quick Ratio2.40
Current Ratio2.63
Debt/Eq1.05
LT Debt/Eq1.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.99
EPS next Y-0.69
EPS next Q-0.19
EPS this Y-14.77%
EPS next Y24.91%
EPS next 5Y10.72%
EPS past 3/5Y-106.02% -63.72%
Sales past 3/5Y6.90% 8.30%
EPS Y/Y TTM-69.76%
Sales Y/Y TTM-10.81%
EPS Q/Q33.16%
Sales Q/Q-39.47%
EarningsNov 05 AMC
EPS/Sales Surpr.54.30% -11.42%

Ownership

Insider Own0.53%
Insider Trans101.40%
Inst Own40.16%
Inst Trans1.55%
ROA-41.81%
ROE-120.74%
ROIC-52.22%
Gross Margin52.21%
Oper. Margin-46.54%
Profit Margin-59.75%
SMA20-14.12%
SMA50-16.60%
SMA200-20.64%
Trades-

Technical

Shs Outstand47.22M
Shs Float46.97M
Short Float0.78%
Short Ratio3.19
Short Interest0.37M
52W High6.40 -45.31%
52W Low1.92 82.29%
Volatility13.55% 7.96%
ATR (14)0.33
RSI (14)36.43
Beta0.00
Rel Volume0.00
Avg Volume114.37K
Volume0

Performance

Perf Week-14.84%
Perf Month-18.60%
Perf Quarter-26.32%
Perf Half Y-14.22%
Perf YTD6.38%
Perf Year72.41%
Perf 3Y-30.28%
Perf 5Y-39.55%
Perf 10Y12.90%
Recom2.00
Target Price8.38
Prev Close3.50
Price3.50
Change %0.00%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Jul 17, 2026InitiatedMMizuhoOutperform$15+328.6%
May 15, 2025DowngradePPiper SandlerOverweight → Neutral
Apr 04, 2025DowngradeJJefferiesBuy → Hold$2-42.9%
Nov 01, 2022InitiatedJJefferiesBuy$11+214.3%
Apr 28, 2021InitiatedPPiper SandlerOverweight$13+271.4%
Apr 15, 2020InitiatedBB. Riley FBRBuy$5.50+57.1%
Jul 28, 2014DowngradeNNorthland CapitalOutperform → Market Perform$6 → $3.500.0%
Jun 16, 2014InitiatedHH.C. WainwrightBuy$6+71.4%
Mar 05, 2013InitiatedNNorthland CapitalOutperform$6+71.4%
Nov 18, 2010ReiteratedMMorgan JosephBuy$3 → $5.25+50.0%

Peers

Mkt cap
TickerCompanyMkt cap
PROFProfound Medical Corp280.59M
PRCTProcept BioRobotics Corp1.33B
BSXBoston Scientific Corp64.02B
SNWVSanuwave Health Inc16.34M
URGNUroGen Pharma Ltd1.25B
TFXTeleflex Incorporated6.21B
ARAYAccuray Inc9.82M
ICCMIcecure Medical Ltd2.74M
HSICHenry Schein Inc9.81B
ISRGIntuitive Surgical Inc155.64B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Horn David R.DirectorAug 14 '26Buy4.7510,00047,50010,000Aug 17 06:06 AM
Schulz FranDirectorAug 14 '26Buy4.7510,00047,50015,100Aug 17 06:04 AM
LEVINE JOSHUADirectorAug 14 '26Buy4.7510,00047,50045,000Aug 17 06:04 AM
Mobeck Kenneth S.Chief Financial OfficerAug 14 '26Buy4.755,00023,750181,610Aug 17 06:02 AM
WILLSEY LANCEDirectorAug 14 '26Buy4.7550,000237,5001,291,780Aug 17 06:01 AM
Rhodes RyanChief Executive OfficerAug 14 '26Buy4.7521,00099,750626,649Aug 17 06:01 AM
Shah SanketGeneral Counsel & Corp SecAug 14 '26Buy4.755,00023,75072,500Aug 17 06:01 AM
Annen StevenSVP, Marketing & Product Mgmt.Aug 14 '26Buy4.755,00023,750136,490Aug 17 06:00 AM
LEVINE JOSHUADirectorMay 11 '26Buy4.2210,00042,20035,000May 13 06:03 AM

News

latest 14 of 206
  • FocalTherics Reports Third Quarter 2026 Financial Results (GlobeNewswire) -21.88%
  • FocalTherics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
  • FocalTherics Must Square A Sequential Revenue Dip With A Reaffirmed $50 Million Floor (Earnings Whispers)
  • FocalTherics to Announce Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire) -5.03%
  • FocalTherics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Loading…
  • Edap TMS SA (FOCL) (Q2 2026) Earnings Call Highlights: HIFU Revenue Surges 39% as Company ... (GuruFocus.com)
  • FocalTherics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • FocalTherics Announces Pricing of Public Offering of American Depositary Shares (GlobeNewswire) -20.97%
  • FocalTherics Reports Preliminary Financial Results for Second Quarter of 2026 (GlobeNewswire)
  • FocalTherics Announces Proposed Public Offering of American Depositary Shares (GlobeNewswire)
  • FocalTherics to Announce Second Quarter 2026 Financial Results on August 13, 2026 (GlobeNewswire)
  • FocalTherics Announces Successful Launch of First Commercial Endometriosis Focal One Program in Europe with Treatment of Initial Patients (GlobeNewswire)
  • FocalTherics Expands Access to Focal One Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.100-0.219-0.1009.8311.094
2026Q22026-08-13-0.390-0.215-0.38613.2015.095
2026Q12026-05-07-0.240-0.205-0.24317.8116.593
2025Q42026-03-25-0.256-0.149-0.25221.9921.403
2025Q32025-11-06-0.149-0.252-0.15715.9615.023
2025Q22025-08-28-0.175-0.211-0.17018.6916.071
2025Q12025-05-15-0.212-0.165-0.19915.1616.573
2024Q42025-03-27-0.054-0.105-0.05521.8220.203
2024Q32024-11-07-0.182-0.163-0.17414.0617.103
2024Q22024-08-28-0.179-0.142-0.17717.6517.732
2024Q12024-05-16-0.131-0.115-0.13316.2315.914
2023Q42024-03-27-0.152-0.044-0.14621.2719.744
2023Q32023-11-09-0.118-0.115-0.11612.5416.164
2023Q22023-08-24-0.141-0.052-0.13815.4817.114
2023Q12023-05-17-0.218-0.032-0.21816.0915.164
2022Q42023-03-30-0.152-0.005-0.14617.0416.794

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.0550.1270.05749.2251.74
2020FY-0.071-0.008-0.06748.9551.32
2021FY0.022-0.0310.02649.0249.89
2022FY-0.0980.062-0.09059.7458.77
2023FY-0.618-0.517-0.61965.4563.89
2024FY-0.548-0.585-0.55268.8766.18
2025FY-0.798-0.679-0.78072.2270.76
2026FY--0.916--50.87
2027FY--0.688--62.00
2028FY--0.568--75.06
2029FY--0.260--103.2
2030FY--0.085--128.42

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0642216.2515.9916.60
2026Q4S2026-11-0440015.9915.2116.60
2026Q4S2026-11-0340115.8715.2116.50
2026Q4S2026-10-2840115.9915.2116.60
2026Q4S2026-10-1240315.9915.2116.60
2026Q4S2026-10-1040315.9815.2016.60
2026Q4S2026-09-2850315.8915.2016.60
2026Q4S2026-08-2150315.9015.2016.60
2026Q4S2026-08-1450216.7215.2020.70
2026Q4S2026-08-1250018.1015.5021.37
2026Q4S2026-07-2750118.1015.5021.37
2026Q4S2026-07-2150118.1115.5021.37
2026Q4S2026-07-1650218.1115.5021.37
2026Q4S2026-06-1940218.5415.5021.37

Estimate history

EPS, annual-0.023-0.0140.057-0.0670.026-0.09-0.619-0.552-0.784-0.9856
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.177-0.055-0.199-0.17-0.157-0.252-0.243-0.386-0.105
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual40.31946.22650.26847.49452.08457.91765.32469.35370.74562.74
Period201720182019202020212022202320242025TTM
Sales, quarterly1721.67314.26918.18416.21921.86417.87713.1859.818
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual28.99828.99829.14229.16533.46636.91137.10437.39237.48247.221
Period201720182019202020212022202320242025MRQ
Shares, quarterly37.10437.39237.39237.39237.39237.48237.48237.48247.221
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue62.7470.7569.3565.3257.9252.0847.4950.2746.23
Cost of Goods Sold Incl. D&A32.8840.6540.6338.9332.4930.3126.5426.7626.27
Gross Profit32.7630.0928.7326.3925.4321.7720.9523.5119.96
Selling, General and Administrative Excl. Other59.0655.3051.6848.4930.7725.2821.4222.1622.32
Research and Development9.4810.139.108.216.045.625.905.295.63
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-29.20-25.21-22.95-22.10-5.35-3.51-0.461.35-2.36
Interest Expense-0.790.260.250.180.060.120.190.13
Unusual Expense0.002.580.000.000.00-0.220.000.00-1.05
Net Income Before Taxes-38.01-29.27-20.75-22.64-2.810.33-1.921.60-0.78
Income Taxes0.230.07-0.180.250.27-0.500.03-0.09-0.39
Consolidated Net Income-38.24-29.34-20.57-22.90-3.080.83-1.941.69-0.40
Net Income From Continuing Operations-38.24-29.34-20.57-22.90-3.080.83-1.941.69-0.40
Net Income-37.49-29.34-20.57-22.90-3.080.83-1.941.69-0.40
EPS (Recurring)-0.88-0.74-0.55-0.62-0.090.02-0.070.06-0.04
EPS (Basic, Before Extraordinaries)-0.99-0.78-0.55-0.62-0.090.03-0.070.06-0.01
EPS (Diluted)-0.99-0.78-0.55-0.62-0.090.03-0.070.06-0.01
EBITDA--21.78-20.15-20.02-3.63-1.242.053.67-0.62
Non-Operating Income (Expense)2.21-0.682.46-0.292.713.67-1.330.440.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.932.665.421.751.65---
Price To Earnings Ratio----93.26247.52-75.08-
Price To Sales Ratio3.041.741.192.996.333.733.172.611.16
Gross Margin52.2142.5441.4240.4043.9041.8144.1146.7643.17
Operating Margin-46.54-35.63-33.10-33.84-9.24-6.74-0.982.68-5.10
Net Margin-59.75-41.47-29.66-35.05-5.321.59-4.093.37-0.86
Shares Outstanding47.2237.4837.3937.1036.9133.4729.1729.1429.00
Market Capitalization165.27165.2782.00194.89389.57199.74150.66128.4653.65

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.8213.1817.8821.8616.2218.1814.2721.67
Cost of Goods Sold Incl. D&A4.775.869.7012.559.2410.458.2811.97
Gross Profit5.057.338.189.316.987.735.999.70
Selling, General and Administrative Excl. Other12.8215.3515.5715.3212.7314.2712.3013.69
Research and Development2.462.312.612.112.442.502.581.99
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.77-8.02-7.39-6.02-5.76-6.54-6.31-3.99
Interest Expense-6.291.723.010.060.06--
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.27-14.38-8.97-9.38-5.74-6.24-7.30-2.08
Income Taxes0.010.010.150.060.120.110.14-0.01
Consolidated Net Income-5.28-14.39-9.12-9.45-5.86-6.35-7.45-2.07
Net Income From Continuing Operations-5.28-14.39-9.12-9.45-5.86-6.35-7.45-2.07
Net Income-4.46-14.47-9.12-9.45-5.86-6.35-7.45-2.07
EPS (Recurring)-0.10-0.39-0.24-0.25-0.16-0.17-0.20-0.06
EPS (Basic, Before Extraordinaries)-0.10-0.39-0.24-0.25-0.16-0.17-0.20-0.06
EPS (Diluted)-0.10-0.39-0.24-0.25-0.16-0.17-0.20-0.06
EBITDA-6.77-7.02-6.49-----
Non-Operating Income (Expense)2.50-0.080.14-0.360.070.36-0.991.91
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.950.640.24-----
Price To Sales Ratio3.042.811.881.751.22---
Gross Margin51.4055.5845.7342.5843.0242.5242.0044.78
Operating Margin-79.14-60.84-41.35-27.51-35.49-35.95-44.22-18.40
Net Margin-45.40-109.73-50.99-43.22-36.13-34.91-52.18-9.55
Shares Outstanding47.2237.4837.4837.4837.3937.3937.3937.39
Market Capitalization165.27194.16139.43123.0285.6361.7073.2982.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments20.4530.9048.0267.3853.6630.2223.4422.2524.02
Short Term Receivables22.5821.0121.2515.9513.7815.1014.1315.2214.82
Inventories12.8319.1516.6912.578.539.779.188.248.09
Other Current Assets1.301.300.730.700.660.450.500.440.59
Total Current Assets57.1672.3686.6996.6176.6355.5447.2546.1647.52
Net Property, Plant & Equipment13.5010.709.056.395.886.857.544.814.42
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable0.55----0.000.000.030.09
Intangible Assets4.633.623.863.353.573.883.573.733.53
Deferred Tax Assets1.090.860.810.881.020.460.480.370.20
Other Assets2.061.570.720.700.720.800.720.630.55
Total Assets79.0089.12101.13107.9287.8267.5359.5755.7256.31
Short Term Debt Incl. Current Port. of LT Debt9.3510.175.714.894.2710.185.985.214.03
Accounts Payable11.7813.0612.417.096.276.986.797.207.58
Income Tax Payable0.19-0.010.090.230.570.160.310.130.18
Other Current Liabilities15.8115.9312.2710.969.308.996.566.687.59
Total Current Liabilities37.1439.1530.4823.1720.4126.3119.6419.2219.37
Long Term Debt18.334.253.665.137.113.423.742.501.64
Provision for Risks Charges0.000.000.000.002.883.132.753.123.17
Other Liabilities4.113.374.113.170.501.211.531.150.67
Total Liabilities59.5846.7738.2531.4730.9034.0727.6625.9924.86
Non-Equity Reserves0.000.000.000.000.001.341.201.191.25
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity19.4142.3562.8876.4556.9232.1230.7128.5430.21
Total Shareholders Equity19.4142.3562.8876.4556.9232.1230.7128.5430.21
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity19.4142.3562.8876.4556.9232.1230.7128.5430.21
Total Liabilities & Stockholders Equity79.0089.12101.13107.9287.8267.5359.5755.7256.31
Book Value Per Share0.521.131.692.071.701.101.050.981.04
Tangible Book Value Per Share0.391.041.591.981.590.970.930.860.92
Full-Time Employees289310307264227223216215200
Price to Book Ratio4.601.613.064.943.525.114.501.882.87
Return on Assets-34.90-21.63-21.90-3.151.07-3.062.94-0.71-1.46
Return on Equity-95.00-39.10-32.87-4.621.86-6.185.71-1.36-2.74
Return on Invested Capital-77.72-44.15-34.41-3.781.29-5.474.91-1.28-2.41
Quick Ratio1.191.362.303.633.341.741.941.972.04
Current Ratio1.541.852.844.173.752.112.412.402.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-37.41-29.34-20.57-22.90-3.080.83-1.941.69-0.40
Depreciation-3.422.772.071.692.272.402.101.90
Other Funds (Non Cash)14.286.755.338.052.702.211.870.570.39
Funds from Operations-20.20-19.40-12.57-12.731.364.642.384.251.71
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital7.132.94-2.12-3.14-4.540.62-0.120.01-1.50
Cash from Operating Activities-13.08-16.46-14.69-15.87-3.185.262.254.250.21
Capital Expenditures-5.22-5.78-1.67-1.85-0.79-0.57-0.72-0.48-1.23
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.180.000.000.000.000.000.000.000.42
Purchase or Sale of Investments0.000.000.000.000.000.02-0.00-0.020.00
Purchase of Investments0.000.000.000.000.000.00-0.00-0.020.00
Sale Or Maturity of Investments0.000.000.000.000.000.020.000.000.00
Other Uses-0.020.00-2.79-2.85-1.71-1.38-1.57-1.22-1.05
Other Sources0.040.040.000.000.000.000.00--
Cash from Investing Activities-5.06-5.73-4.46-4.70-2.50-1.94-2.29-1.71-1.85
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Change in Capital Stock43.150.000.130.2823.8025.690.070.350.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock43.150.000.130.2823.8025.690.070.350.00
Proceedsfrom Stock Options43.150.000.000.0023.0825.160.000.000.00
Issuance or Reduction of Debt, Net-8.644.89-1.27-0.95-1.733.58-1.091.39
Change in Long Term Debt-9.520.87-1.98-0.91-0.894.93-0.450.69
Issuance of Long Term Debt-12.452.800.000.301.255.530.771.22
Reduction of Long Term Debt--2.93-1.93-1.98-1.21-2.14-0.59-1.22-0.52
Net Financing Active Other Cash Flow0.000.000.000.00-0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-0.000.000.000.000.00
Cash from Financing Activities62.228.645.01-0.9822.8523.953.65-0.741.39
Exchange Rate Effect-0.612.98-0.610.29-0.41-0.690.73-0.20-0.38
Net Change in Cash43.47-10.58-14.75-21.2616.7726.584.341.59-0.64
Free Cash Flow-18.30-21.40-16.12-17.14-3.824.791.653.81-0.51
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----40.5491.4234.44-
Deferred Taxes & Investment Tax Credit--0.23-0.100.050.05-0.670.05-0.12-0.18

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments56.2721.5415.0120.4512.4219.09
Short Term Receivables10.8010.7120.3322.5822.3521.75
Inventories8.338.2513.3312.8316.2118.23
Other Current Assets19.3918.511.691.301.131.36
Total Current Assets94.7859.0250.3657.1652.1160.43
Net Property, Plant & Equipment10.4110.1413.0113.5011.7711.98
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.562.514.504.632.832.83
Deferred Tax Assets0.260.271.081.09--
Other Assets1.721.622.082.065.504.99
Total Assets110.7274.5572.0679.0072.2280.22
Short Term Debt Incl. Current Port. of LT Debt1.743.657.849.355.937.37
Accounts Payable10.9410.3512.5411.7819.7921.77
Income Tax Payable-0.000.180.19--
Other Current Liabilities23.3922.8616.9515.8111.1810.91
Total Current Liabilities36.0736.8537.5137.1436.9040.05
Long Term Debt35.8538.0319.9518.332.943.15
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.862.894.504.114.984.37
Total Liabilities74.7877.7761.9659.5844.8247.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity35.94-3.2310.1019.4127.4032.66
Total Shareholders Equity35.94-3.2310.1019.4127.4032.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity35.94-3.2310.1019.4127.4032.66
Total Liabilities & Stockholders Equity110.7274.5572.0679.0072.2280.22
Book Value Per Share0.76-0.090.270.520.730.87
Tangible Book Value Per Share0.71-0.150.150.390.660.80
Full-Time Employees---289--
Price to Book Ratio4.6019.227.184.492.621.66
Return on Assets-41.81-50.16-40.21-34.62--
Return on Equity-120.74-263.75-130.05-94.24--
Return on Invested Capital-6.21-41.56-30.34-25.03-19.31-17.73
Quick Ratio2.401.380.991.190.971.05
Current Ratio2.631.601.341.541.411.51

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.45-14.48-9.12-9.37-6.16-6.33
Depreciation1.001.000.90---
Other Funds (Non Cash)-2.248.383.384.752.171.77
Funds from Operations-3.76-6.10-5.74-4.62-4.00-4.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.262.412.752.23-0.07-0.09
Cash from Operating Activities-4.02-3.69-2.98-2.38-4.07-4.65
Capital Expenditures-1.51-1.26-0.76-2.53-1.13-1.60
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.00-0.000.180.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-0.00-0.01-0.010.000.000.00
Other Sources0.000.000.000.040.000.00
Cash from Investing Activities-1.34-1.26-0.76-1.70-1.13-1.60
Cash Dividends Paid0.000.000.00--0.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock43.130.020.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock43.130.020.000.000.000.00
Proceedsfrom Stock Options43.130.020.000.000.000.00
Issuance or Reduction of Debt, Net-2.8111.77-1.38--0.00
Change in Long Term Debt-0.6213.34-0.70--0.00
Issuance of Long Term Debt-0.0113.980.00--0.00
Reduction of Long Term Debt-0.62-0.63-0.70--0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities40.3211.79-1.3811.49-1.680.06
Exchange Rate Effect-0.21-0.29-0.340.23-0.09-1.19
Net Change in Cash34.746.55-5.467.64-6.97-7.37
Free Cash Flow-5.53-4.95-3.74-4.08-5.20-6.25

Revenue breakdown

Consolidation, Policy2024: -1.00K
Goods2024: 47.66M 2025: 48.90M
RPP's and leases2024: 8.24M 2025: 10.29M
Spare parts and services2024: 13.50M 2025: 11.34M
Asia2024: 20.61M 2025: 19.57M
Consolidation, Policy2025: 1.00K
France2024: 12.17M 2025: 4.59M
Other geographical Areas2024: 16.90M 2025: 17.85M
United States2024: 19.72M 2025: 28.53M
Consolidation, Policy2024: -1.00K 2025: 1.00K
Distribution (DISTRIB) Division2024: 33.87M 2025: 25.71M
High Intensity Focused Ultrasound (HIFU)2024: 25.80M 2025: 37.35M
Lithotripsy (ESWL)2024: 9.72M 2025: 7.46M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.98%0.4M37.3M108.89K
2026-10-150.90%0.3M37.3M113.32K
2026-09-300.70%0.3M37.3M112.48K
2026-09-150.66%0.2M37.3M106.19K
2026-08-310.76%0.3M37.3M99.13K
2026-08-140.52%0.2M37.3M77.65K
2026-07-310.69%0.3M37.3M47.80K
2026-07-150.63%0.2M37.3M40.89K
2026-06-300.51%0.2M37.3M37.21K
2026-06-150.36%0.1M37.3M35.96K
2026-05-150.15%0.1M37.4M40.57K
2026-04-300.09%0.0M37.4M49.20K
2026-04-150.10%0.0M37.4M59.07K
2026-03-310.15%0.1M37.4M68.60K
2026-03-130.12%0.0M37.3M75.15K
2026-02-270.16%0.1M37.3M75.38K
2026-02-130.24%0.1M37.3M72.88K
2026-01-300.20%0.1M37.3M64.59K
2026-01-150.25%0.1M37.3M62.43K
2025-12-310.29%0.1M37.2M60.19K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.601.351.803.88710.000.000.906-0.0090.001
call5.000.000.050.051.5561510.000.120-0.0090.001
call7.500.000.050.202.8362110.000.080-0.0120.001
call10.000.001.000.003.5820.000.000.068-0.0140.001
put2.500.000.050.074.11621.000.00-0.208-0.0340.002
put5.001.151.900.003.5970.000.00-0.880-0.0090.001
put7.503.404.600.006.0680.000.00-0.920-0.0120.001
put10.005.807.300.007.9350.000.00-0.932-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-19SCHEDULE 13GSEC
2026-09-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-203Initial statement of beneficial ownership of securities2026-01-01SEC
2026-08-198-KCurrent report2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-11SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-12424B5SEC
2026-08-12424B5SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-06-268-KCurrent report2026-06-26SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-298-KCurrent report2026-05-29SEC
2026-05-14ARSAnnual report to security holders. 2025-12-31SEC
2026-05-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-26SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08551.00K800
2026-070000
2026-060000
2026-0542.20K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Soleus Capital Management, L.P.19.50%
AIGH Capital Management LLC9.30%
MORGAN STANLEY8.90%
FLAX POND CAPITAL, LLC4.07%
Rock Springs Capital Management LP3.70%
ESSEX INVESTMENT MANAGEMENT CO LLC1.35%
Bruce & Co., Inc.1.17%
PERKINS CAPITAL MANAGEMENT INC0.49%
Parkman Healthcare Partners LLC0.41%
CAHILL FINANCIAL ADVISORS INC0.36%

Funds

Fund% owned
BRUCE FUND1.11%
1290 Essex Small Cap Growth Fund0.33%
Fidelity Nasdaq Composite Index Fund0.07%

OakChart. FOCL. Cached 15 minutes.